FAST Supports UPenn Research Into microRNA as Angelman Therapy
The Foundation for Angelman Syndrome Therapeutics (FAST) has opened a program supporting new research into treating Angelman syndrome by using microRNA (miRNA) to boost UBE3A protein levels. FAST will collaborate with the Gene Therapy Program at the University of Pennsylvania (UPenn) to design this potential therapy, the organization…